Ads
related to: how quickly do antivirals work on herpes outbreak infection disease list
Search results
Results From The WOW.Com Content Network
List of Antiviral Drugs Antiviral Use Manufacturer Component Type Year approved Abacavir: HIV: ViiV Healthcare: Nucleoside analogue reverse transcriptase inhibitor (NRTI) 1998 Acyclovir (Aciclovir) Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 ...
Herpes gladiatorum is a skin infection primarily caused by the herpes simplex virus. The virus infects the cells in the epidermal layer of the skin. The initial viral replication occurs at the entry site in the skin or mucous membrane. [7] The infections caused by a HSV Type 1 virus may be primary or recurrent. [8]
The first successful antiviral, aciclovir, is a nucleoside analogue, and is effective against herpesvirus infections. The first antiviral drug to be approved for treating HIV, zidovudine (AZT), is also a nucleoside analogue. An improved knowledge of the action of reverse transcriptase has led to better nucleoside analogues to treat HIV infections.
An example of this is herpetic whitlow, which is a herpes infection on the fingers; it was commonly found on dental surgeon's hands before the routine use of gloves when treating patients. Shaking hands with an infected person does not transmit this disease. [24] Genital infection of HSV-2 increases the risk of acquiring HIV. [25]
Aciclovir, also known as acyclovir, [4] is an antiviral medication. [5] It is primarily used for the treatment of herpes simplex virus infections, chickenpox, and shingles. [6] Other uses include, prevention of cytomegalovirus infections following transplant, and severe complications of Epstein–Barr virus infection.
Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG.